NDAOPHTHALMICGEL
Approved
Oct 2008
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
5/8 — Partial
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTEN is a topical ophthalmic gel formulation of lidocaine hydrochloride anhydrous approved in 2008 for local anesthesia in the eye. It is a small-molecule local anesthetic that reversibly blocks sodium channels in nerve membranes to produce anesthesia. The product is indicated for ocular surface anesthesia prior to diagnostic or surgical procedures.
$0.001BPart D
Post-LOEDeclining
Post-LOEMinimal commercial investment as product is post-exclusivity with very low Part D utilization and declining market presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Thea Pharma is hiring 1 role related to this product
Worked on AKTEN at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.